Mark J. Mann, MD, assistant professor, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses the differences between treatment options for patients with prostate cancer subtypes.
Mark J. Mann, MD
Advertisement
Articles by Mark J. Mann, MD
Mark J. Mann, MD, assistant professor, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses the future of immunotherapy in prostate cancer.
Advertisement
Latest Updated Articles
Dr. Mann on Immunotherapy Developments in Prostate CancerPublished: March 19th 2018 | Updated:
Dr. Mann on Differences Between Treatments for Prostate CancerPublished: March 23rd 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5